The Promise of Gene Therapy - Takeaways - MDSpire

The Promise of Gene Therapy

With phase 3 topline data for sura-vec expected later this year, Arshad M. Khanani, MD, FASRS, reflects on how gene therapy could transform long-term treatment for nAMD.

  • By

  • Arshad M. Khanani, MD, MA, FASRS

  • July 15, 2026

  • 2 min

Share

  • 1

    Arshad M. Khanani, MD, FASRS, discussed the potential of gene therapy for treating wet age-related macular degeneration (nAMD) at the ASRS 2026 meeting.

  • 2

    RGX-314, also known as sura-vec, is a gene therapy that may reduce the treatment burden for patients with nAMD.

  • 3

    Long-term data for RGX-314 was presented at the meeting, highlighting its promise as a drug delivery platform.

  • 4

    Phase 3 data from the sura-vec program is expected later this year, which could influence clinical practice.

  • 5

    Gene therapy could significantly improve treatment outcomes for nAMD patients by potentially reducing the need for chronic injections.

Original Source(s)

The Promise of Gene Therapy

  • by Arshad M. Khanani, MD, MA, FASRS

  • July 15, 2026

Related Content

Femtosecond laser-assisted LASIK in the SMILE era: a mini review of patient-centered procedure selection

Long-term Impact of Intravitreal Injections on the ocular surface; a 2-year follow-up study

The Economics of Home OCT

At ASRS 2026, Sean Berkowitz, MD, MBA, examined the payer costs and physician workload associated with home OCT monitoring for wet AMD.